Streeterville Capital

Streeterville Capital

Streeterville Capital was founded in 2010 and is headquartered in Long Beach, California. The firm is led by John M. Fife, who serves as Chief Investment Officer, and his son Matthew C. Fife as President. The firm does not publicly disclose a wealth origin or family-backing source, and its ownership structure remains opaque beyond the principals named in SEC filings. John M. Fife's experience spans banking and private credit. Streeterville Capital acts as a structured finance provider, writing convertible notes, promissory notes, and equity-linked instruments for micro-cap and small-cap companies. The firm's documented deals include investments in companies like Moleculin Biotech, Equillium, and Creative Medical Technology Holdings — all publicly disclosed through SEC filings and press releases. The geographic focus is exclusively North America, with a concentration in U.S.-listed securities. The firm has reported deploying over $500 million in aggregate across its track record (per SEC filings, 2023). Approved as a funding vehicle for micro-cap issuers needing bridge or growth capital, Streeterville often files beneficial ownership reports when surpassing 5% of a public company's outstanding shares. It does not maintain a known philanthropic foundation or operating-company subsidiaries. Streeterville Capital's structural differentiator is its niche as a non-bank lender to micro-cap public companies — a segment under-served by traditional banks and most family offices. The firm builds portfolios of short-dated, high-yield convertible or structured debt instruments, positioning it more as a specialty finance firm than a multi-asset allocator. It typically structures each deal on a case-by-case basis, avoiding a formulaic fund architecture. Regulatory filings show the principals hold securities directly or through investment vehicles, lending added transparency relative to pure private vehicle structures.